Lantern Pharma Launches AI Module to Predict Efficacy of Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR® platform designed to predict the efficacy of combination therapies involving DNA-damaging agents and DNA damage response inhibitors. This advancement is supported by a peer-reviewed analysis of 221 clinical trials, providing robust validation for the tool's predictive capabilities. The technology enables precise, biomarker-guided design of cancer treatment regimens, which could significantly reduce development time and cost by up to one-third compared to traditional methods.

The platform has already demonstrated practical application by guiding the design of Lantern's FDA-cleared Phase 1B/2 trial in triple-negative breast cancer, combining LP-184 and olaparib. This successful implementation showcases how AI can accelerate and optimize clinical trial design while improving therapeutic outcomes. The company is actively exploring licensing and commercialization opportunities to scale the system across multiple oncology indications, potentially transforming how combination therapies are developed and deployed in cancer treatment.

For investors seeking additional information, the latest updates relating to LTRN are available through the company's newsroom at https://ibn.fm/LTRN. The full press release detailing this technological advancement can be accessed at https://ibn.fm/SWNHJ. This development represents a significant step forward in leveraging artificial intelligence to address complex challenges in oncology drug development and personalized cancer treatment approaches.